Mason Carrico
Stock Analyst at Stephens & Co.
(3.57)
# 828
Out of 5,064 analysts
77
Total ratings
48.53%
Success rate
6.82%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $230.63 | +1.89% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $2.22 | -9.91% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $74.36 | +2.21% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.48 | -4.18% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $39.54 | +69.45% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $123.85 | -15.22% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $18.34 | -23.66% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $17.18 | +132.83% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $99.62 | +15.44% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $44.01 | +2.25% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $105.42 | -47.83% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.88 | +2.04% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $28.00 | -39.29% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $67.99 | -23.52% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $7.38 | +171.00% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $37.88 | +8.24% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $230.63
Upside: +1.89%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $2.22
Upside: -9.91%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $74.36
Upside: +2.21%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.48
Upside: -4.18%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $39.54
Upside: +69.45%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $123.85
Upside: -15.22%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $18.34
Upside: -23.66%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $17.18
Upside: +132.83%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $99.62
Upside: +15.44%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $44.01
Upside: +2.25%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $105.42
Upside: -47.83%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.88
Upside: +2.04%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $28.00
Upside: -39.29%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $67.99
Upside: -23.52%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $7.38
Upside: +171.00%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $37.88
Upside: +8.24%